First‑Line Short‑Acting Beta‑Agonist Choice for Asthma and COPD

Clinical Equivalence and Recommended Agent

Standard salbutamol (albuterol) should be used as the first‑line rescue short‑acting beta‑agonist (SABA) for both asthma and COPD because it is clinically equivalent to levosalbutamol, costs less, and is the only agent with validated safety data for continuous nebulization in severe exacerbations. 1

When dosed appropriately, salbutamol and levosalbutamol provide interchangeable efficacy and safety. [1][2]
Salbutamol dosing: 2.5–5 mg nebulized or 2 puffs (200 µg per puff) via metered‑dose inhaler (MDI). [3][4]
Levosalbutamol dosing: 1.25–2.5 mg nebulized or 1 puff (45 µg per puff) via MDI. [3][4]

Both agents have an onset of action ≤ 5 minutes, peak bronchodilation at 30–60 minutes, and a duration of effect of 4–6 hours. 1

At equipotent doses, the side‑effect profiles of salbutamol and levosalbutamol are essentially identical. [1][2]
Common dose‑dependent adverse effects include tremor, anxiety, tachycardia, hypokalemia, headache, and hyperglycemia. [3][4]
Levosalbutamol does not provide a clinically meaningful reduction in these side effects despite theoretical advantages. [1][2]
Inhaled administration of either drug results in minimal systemic adverse effects. [3][4]

Levosalbutamol has never been studied for continuous nebulization; only salbutamol has guideline support and safety data for continuous delivery (10–15 mg/hour) in life‑threatening asthma or COPD exacerbations. 5

Levosalbutamol is approximately 35 % more expensive than salbutamol (≈ $54 vs $40–55 per inhaler) without demonstrable clinical benefit. 1
The theoretical benefit of removing the S‑enantiomer has not translated into meaningful clinical advantage in well‑designed trials. 2

Routine rescue: Salbutamol 2 puffs (200 µg each) via MDI with spacer every 4–6 hours as needed. [3][4]
An MDI with spacer is equally effective as a nebulizer when proper technique is used. 1
Acute asthma exacerbation: Add ipratropium bromide 0.5 mg to the first three salbutamol doses for a modest additional benefit. [2][5]

Overuse of SABAs (> 2 days per week, excluding exercise‑related use) signals poor asthma control and warrants escalation of controller therapy. [5][6]
Six to ten puffs from an MDI with spacer approximate one nebulizer treatment; two puffs are not equivalent. 1
Scheduled use of a SABA ≥ 4 times daily shortens its duration of action without increasing potency; use only on an as‑needed basis. 1

The National Asthma Education and Prevention Program (NAEPP) and American College of Allergy, Asthma, and Immunology state that both drugs are acceptable SABAs, with levosalbutamol administered at half the milligram dose of salbutamol to provide comparable efficacy and safety 7
Levosalbutamol has a critical limitation: it has not been evaluated for continuous nebulization, which is essential for severe status asthmaticus and acute COPD exacerbations 7
For continuous nebulization protocols, only standard salbutamol has guideline support 7
The American College of Allergy, Asthma, and Immunology recommends choosing between salbutamol and levosalbutamol based on availability and cost, as they are clinically equivalent 7

For acute asthma exacerbations, salbutamol 2.5-5 mg nebulized every 20 minutes for 3 doses, then every 1-4 hours as needed, with the addition of ipratropium bromide 0.5 mg to the first 3 doses for additional benefit (Grade A evidence) 8, 7
For acute COPD exacerbations, salbutamol 2.5-5 mg nebulized every 20 minutes initially, with no additional benefit from adding anticholinergics to beta-agonists (Grade A evidence) 8, 9
For chronic stable COPD, long-acting bronchodilators (LAMA/LABA combinations) are preferred over short-acting agents for maintenance therapy, with short-acting bronchodilators like salbutamol used as needed (prn) for breakthrough symptoms 10, 11

Hand-held inhalers with spacer devices and proper technique are equally effective as nebulizers for achieving bronchodilation in acute asthma or COPD exacerbations (Grade A evidence) 8, 9
Do not use oral corticosteroids long-term in COPD (Evidence A) 10
For patients with heart failure and concomitant COPD/asthma, cardioselective beta-blockers (bisoprolol, metoprolol, nebivolol) are preferred and can be safely used with inhaled beta-agonists when started at low doses with gradual titration 12, 13

Initial treatment choice: Use salbutamol 2.5-5 mg nebulized or via MDI with spacer 8, 7
If severe/life-threatening: Continue salbutamol every 20 minutes × 3 doses, then consider continuous nebulization at 10-15 mg/hour (only salbutamol studied for this) 7
If levosalbutamol is chosen: Use half the milligram dose (1.25-2.5 mg), but only for intermittent dosing, not continuous nebulization 7
Add ipratropium: 0.5 mg to first 3 doses in acute asthma only (not proven beneficial in acute COPD) 8, 7